RxDoctor Payments Data

Timothy Martin, DO

Neurology · Lancaster, PANPI 1750355822

Payments from drug & device makers

$1,317in general payments, 2019–2025

Across 39 payments — averaging $33.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$171
  • Novartis$165
  • Impel Pharmaceuticals Inc.$160
  • Bristol Myers Squibb$148
  • Boston Scientific$138
  • Harmony Biosciences LLC$120
  • plus $413 from 10 others

What the payments were for

  • Speaking & faculty fees$242%
  • Food & beverage$1,29398%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,317 in reported general payments places this provider in the 50th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$7,072
Medicare patients
54
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dimethyl Fumarate19$18,152
Dalfampridine ErDalfampridine13$15,626
Emgality PenGalcanezumab-Gnlm17$11,365
Lacosamide21$5,143
DilantinPhenytoin Sodium Extended18$3,011
Gabapentin69$2,211
Carbidopa-LevodopaCarbidopa/Levodopa51$2,047
Levetiracetam47$1,933
Divalproex Sodium ErDivalproex Sodium39$1,558
Carbamazepine ErCarbamazepine13$1,251
Carbidopa-Levodopa ErCarbidopa/Levodopa19$1,221
Lamotrigine ErLamotrigine14$1,167
Baclofen17$870
Pyridostigmine Bromide13$864
Propranolol Hcl ErPropranolol Hcl18$785

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCPyridostigmine Bromide$16$86413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →